HSV

SCH-43478 is a non-nucleoside antiviral agent that targets herpes simplex virus type 2 (HSV-2). It exhibits potent and selective activity with an IC50 of 1.8 μg/mL in Vero cells. Additionally, SCH-43478 shows significant efficacy in preclinical models of HSV infection, specifically in the guinea pig genital model, making it a valuable tool for research on antiviral therapies.

HSV-1/HSV-2-IN-3 is a potent inhibitor of the herpes simplex virus (HSV) helicase-primase complex, effectively disrupting the DNA unwinding and primer synthesis necessary for viral genome replication. It demonstrates an EC50 of 7.0 nM against HSV-2 in gD-immunofluorescence assays, and 1.1 nM in qPCR replication assays, highlighting its potent antiviral activity. Additionally, HSV-1/HSV-2-IN-3 exhibits high selectivity for viral targets, with an IC50 of approximately 2.9 µM for human carbonic anhydrase II, making it a valuable tool for anti-HSV research applications.

(S)-HN0037 is a selective helicase-primase inhibitor that effectively targets the viral helicase-primase complex, thereby inhibiting herpes simplex virus (HSV) replication. Its oral bioactivity makes it a valuable tool for studying HSV pathology and developing antiviral therapies. Researchers can utilize (S)-HN0037 in various experimental models to investigate mechanisms of viral replication and explore potential therapeutic interventions against HSV infections.

C-AFG is a novel herpes simplex virus (HSV) inhibitor that demonstrates potent activity against both HSV-1 and HSV-2. This compound exhibits high selectivity, making it a valuable tool for research on viral infections and the mechanisms of antiviral action. C-AFG is suitable for studies focusing on therapeutic strategies against herpesvirus-related diseases.

HSV-1-IN-3 is a potent inhibitor of herpes simplex virus (HSV) with demonstrated antiviral activity against both Acyclovir-sensitive and -resistant HSV strains. This compound has potential applications in virology research, particularly in studies focused on understanding and developing treatments for HSV infections. Its effectiveness against resistant strains makes it a valuable tool in the search for new antiviral therapies.

Woodorien is a potent inhibitor of herpes simplex virus type 1 (HSV-1), demonstrating strong antiviral activity. Isolated from the plant Woodwardia orientalis, Woodorien functions as a glucoside that impacts viral replication. This compound serves as a valuable tool for studying HSV-1 infection mechanisms and the development of antiviral therapies.

Rociclovir is an acyclic nucleoside derivative that functions as an inhibitor of herpes simplex virus (HSV) and murine cytomegalovirus (MCMV). It has demonstrated protective effects in murine models against HSV and MCMV infections. However, it is important to note that Rociclovir exhibits limited antiviral activity in cell culture systems, highlighting its primary utility in in vivo research applications.

Cycloviracin B1 is a potent inhibitor of herpes simplex virus type 1 (HSV-1), demonstrating significant antiviral activity against this pathogen. In addition to its primary application in virology, it exhibits weak anti-Gram-positive bacterial activity, which may provide further avenues for research. This compound is valuable for studies focused on HSV-1 infection and potential therapeutic interventions.

Arabinosylhypoxanthine is a purine nucleoside analog that selectively inhibits viral DNA synthesis. It demonstrates significant anti-herpes simplex virus (HSV) activity, making it a valuable tool for research on herpes simplex virus infections. This compound can be utilized to investigate mechanisms of antiviral action and to develop therapeutic strategies against HSV.

Adipic acid (Hexanedioic acid) primarily functions as an anti-HSV agent, exhibiting effective antiviral activity against HSV-1. This compound is characterized by its low toxicity, making it suitable for applications as a food additive and gelling agent. Additionally, adipic acid serves as an important intermediate in the synthesis of lubricants, artificial resins, and plastics, highlighting its versatility in chemical research and industrial applications.

Famciclovir(BRL 42810) is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections.

Levamisole hydrochloride is an anthelmintic and immunomodulator belonging to a class of synthetic imidazothiazole derivatives.

HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope.

ASP2151, is a herpes virus helicase-primase inhibitor. ASP2151 had significantly better anti-HSV activity against herpes simplex keratitis than valacyclovir and acyclovir after systemic or topical use.

BAY 57-1293 is a potent helicase primase inhibitor. BAY 57-1293 inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex.

Fiacitabine is a selective inhibitior of DNA replication of herpes simplex virus(HSV) with IC50 values of 2.5 nM and 12.6 nM for HSV1 and HSV2, respectively.

Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM.

Penciclovir is reported to be potent against HSV types 1 and 2 with IC50 of 0.04-1.8 μg/mL and 0.06-4.4 μg/mL, respectively.

Helioxanthin 8-1 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 uM.

Cyclopropavir (Filociclovir; ZSM-I-62; MBX-400) is a broad-spectrum anti-herpesvirus compound, has good antiviral activity against cytomegalovirus (CMV), herpes simplex virus (HHV)-6 and HHV-8 with EC50s of 0.7 ??M to 8 ??M.

B220 is an antiviral agent which can inhibit the growth of HSV-1, HSV-2 and human cytomegalovirus (CMV).

HSV-TK substrate is a substrate for HSV-TK, and induces multi-log cytotoxicity in HSV-TK-expressing and bystander cells. HSV-TK substrate shows antitumor activity.

AT-533 is a potent inhibitor of heat shock protein 90 (Hsp90) and herpes simplex virus (HSV), exhibiting strong antitumor and antiviral activities. It suppresses tumor growth and angiogenesis by disrupting the HIF-1α/VEGF/VEGFR-2 signaling axis, a critical pathway in tumor vascularization and progression. Additionally, AT-533 inhibits key downstream signaling cascades, including Akt/mTOR/p70S6K, ERK1/2, and FAK pathways. In endothelial cells, specifically human umbilical vein endothelial cells (HUVECs), AT-533 effectively inhibits tube formation, cell migration, and invasion, highlighting its anti-angiogenic properties. These combined effects position AT-533 as a promising candidate for cancer therapy and angiogenesis-related disease research.

Brassicasterol is a metabolite of Ergosterol that primarily targets androgen pathways and exhibits antiviral activity against HSV-1. It demonstrates significant anticancer potential in prostate cancer by dual modulation of AKT and androgen receptor signaling pathways. Additionally, Brassicasterol inhibits sterol δ 24-reductase, contributing to the slowdown of atherosclerosis progression. Furthermore, it serves as a cerebrospinal fluid biomarker for Alzheimer's disease, highlighting its relevance in neurodegenerative research.